Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression
The Journal of Clinical Psychiatry April 20, 2020 Ewa Wajs, Leah Aluisio, Richard Holder et al. 288 citations
OBJECTIVE: To evaluate long-term safety and efficacy of esketamine nasal spray plus a new oral antidepressant (OAD) in patients with treatment-resistant depression (TRD). METHODS: This phase 3, open-label, multicenter, long-term (up to 1 year) study was conducted between October 2015 and October 2017. Patients (≥ 18 years) with TRD (DSM-5 diagnosis of major depressive disorder and nonresponse...